European Bank for induced pluripotent Stem Cells

European Bank for induced pluripotent Stem Cells
Name	European Bank for induced pluripotent Stem Cells
Abbreviation	EBisc
Formation	2013
Type	Biorepository
Headquarters	Cambridge, United Kingdom
Region served	Europe
Leader title	Director

European Bank for induced pluripotent Stem Cells The European Bank for induced pluripotent Stem Cells is a centralized biorepository and distribution platform established to collect, characterize, and provide human induced pluripotent stem cell lines for biomedical research across Europe and internationally. It operates within a matrix of academic, clinical, and industrial stakeholders to support translational programs in regenerative medicine, disease modelling, drug discovery, and toxicology, interfacing with policy frameworks and funding bodies.

History

The initiative emerged from consortia and funding calls involving European Commission programmes such as Horizon 2020 and predecessor frameworks, alongside collaborative networks including EBiSC partners drawn from institutions like Cambridge University Hospitals, Karolinska Institutet, Institut Pasteur, University of Oxford, and ETH Zurich. Early organizational development referenced standards and precedents set by European Bank for Biological Samples projects, collaborative platforms linked to European Molecular Biology Laboratory and European Bioinformatics Institute, and dialogues with regulatory agencies including European Medicines Agency and national competent authorities in United Kingdom, Sweden, France, Germany, and Belgium. Founding stakeholders included university groups from University College London, University of Cambridge, KU Leuven, University of Barcelona, and industry partners such as GlaxoSmithKline and small enterprise consortia linked to Innovate UK. Subsequent growth involved partnerships with disease-focused organisations like Parkinson's UK, MS Society, Alzheimer's Research UK, and pan-European infrastructures such as BBMRI-ERIC and ELIXIR.

Mission and Governance

EBisc’s mission aligns with translational priorities set by European Commission programmes and clinical research networks exemplified by ECRIN and European Clinical Research Infrastructure Network. Governance frameworks integrate advisory input from academic leaders at Imperial College London, Karolinska Institutet, and University of Edinburgh plus regulatory liaisons to MHRA and ANSM. A steering committee has included representatives from philanthropic funders such as Wellcome Trust and European Research Council grant awardees, with scientific oversight informed by consortia including Human Cell Atlas contributors and policy groups linked to Organisation for Economic Co-operation and Development. Operational management liaises with institutional review boards at University Hospital Zurich and ethics committees connected to National Institute for Health and Care Research programmes.

Collections and Cell Lines

The bank curates iPSC lines derived from donors linked to clinical centres such as Mayo Clinic collaborators, neurology clinics affiliated with Charité – Universitätsmedizin Berlin, and cardiology groups at Royal Brompton Hospital. Collections encompass lines modeling disorders referenced in disease registries and networks like European Huntington's Disease Network, EuroBioBank, European Rare Diseases Registry Infrastructure, and condition-focused research consortia including IMI initiatives. Material provenance often traces to biobanks such as BBMRI-ERIC members, clinical trials registered with EudraCT, and cohort studies led by UK Biobank and regional birth cohorts associated with Institut Pasteur and Max Planck Institute for Molecular Genetics. The catalogue includes control lines used by laboratories at Francis Crick Institute, patient-derived lines from University of Milan neurology groups, and genome-edited isogenic pairs produced in collaboration with groups at Broad Institute and Wellcome Sanger Institute.

Quality Control and Standards

EBisc implements quality frameworks informed by standards promulgated by ISO technical committees, and harmonization efforts coordinated with OECD working groups, European Committee for Standardization, and regulatory guidance from European Medicines Agency. Characterization assays mirror best practices from research centres like Institute of Human Genetics, Montpellier and technology hubs such as EMBL-EBI, covering pluripotency marker expression used at laboratories like Stanford University collaborators, karyotyping workflows comparable to those at University of Cambridge, genomic integrity assessments modeled on pipelines from Wellcome Sanger Institute, and mycoplasma testing protocols consistent with standards at Karolinska Institutet. Data standards for phenotypes and assay results are interoperable with metadata schemas maintained by ELIXIR and ontologies developed by Open Biological and Biomedical Ontology Foundry contributors.

Access, Distribution, and Use Policies

Distribution policies reflect material transfer agreements patterned after templates used by Addgene and licensing practices seen at European Molecular Biology Organization member institutions, balancing open research access and commercial use via bespoke agreements co-designed with technology transfer offices at University of Oxford and Karolinska Institutet. Donor consent frameworks reflect models from Council of Europe bioethics instruments and national legislation such as laws in United Kingdom and Germany, with privacy safeguards aligned to General Data Protection Regulation. Access review committees include external experts from European Society of Human Genetics and representatives from patient organisations like Alzheimer Europe and European Federation of Neurological Associations.

Research Contributions and Collaborations

EBisc-supported lines underpin studies published by researchers at University of Oxford, Karolinska Institutet, Heidelberg University Hospital, and international partners including teams at Harvard Medical School, Stanford University School of Medicine, and Yale University. Collaborative projects span disease modelling consortia such as Human Cell Atlas participants, drug screening alliances with GlaxoSmithKline and AstraZeneca, and academic-industrial partnerships involving Novartis and Roche. EBisc contributes materials to multinational efforts like IMI programmes, cohort-based research tied to UK Biobank, and method development coordinated with ELIXIR nodes and the European Molecular Biology Laboratory.

Ethics, Regulation, and Public Engagement

Ethical oversight draws on guidance from bodies such as Nuffield Council on Bioethics, Council of Europe, and national ethics committees including REC panels affiliated with National Institute for Health and Care Research. Regulatory engagement includes interactions with European Medicines Agency and national competent authorities in France, Sweden, and Belgium. Public engagement activities partner with patient groups like Parkinson's UK and Alzheimer Europe, science communication initiatives at Science Museum, London and outreach programmes run by Institute of Science and Technology Austria and university public engagement offices at University of Cambridge. Ongoing debates addressed by EBisc encompass governance themes found in reports by European Group on Ethics in Science and New Technologies and policy recommendations from Organisation for Economic Co-operation and Development.

Category:Biobanks Category:Stem cell research